Table 1.
Demographics and baseline characteristics of the participants for Group A and Group B.
| Group A (n = 45) | ||||
|
MVC-COV1901
(15 mcg) |
MVC-COV1901
(15 mcg, beta) |
MVC-COV1901
(25 mcg, beta) |
p-Value * | |
| Number of participants, n | 15 | 15 | 15 | - |
| Age | - | |||
| Mean (SD) | 36.9 (9.25) | 34.7 (7.71) | 39.5 (9.16) | 0.3309 a |
| Sex | 0.6376 b | |||
| Male | 8 (53.3%) | 11 (73.3%) | 9 (60.0%) | - |
| Female | 7 (46.7%) | 4 (26.7%) | 6 (40.0%) | - |
| Ethnicity | - | |||
| Asian | 15 (100%) | 15 (100%) | 15 (100%) | - |
| BMI | ||||
| Mean (SD) | 24.99 (4.14) | 24.71 (4.09) | 26.21 (5.58) | 0.6454 a |
| Comorbidities | ||||
| HIV-positive | 0 | 0 | 0 | - |
| HBsAg-positive | 0 | 0 | 0 | - |
| Anti-HCV antibody-positive | 0 | 0 | 0 | - |
| Cardiovascular disease | 0 | 0 | 0 | - |
| Cerebrovascular disease | 0 | 0 | 0 | - |
| Malignancy | 0 | 0 | 0 | - |
| HbA1c higher than the normal range (%) | 0 | 1 (6.7%) | 0 | - |
| 1, 2 dose interval (days) mean (SD) | 33.1 (6.55) | 34.5 (4.21) | 32.6 (4.98) | 0.3027 c |
| 2, 3 dose interval (days) mean (SD) | - | - | - | 0.1595 c |
| Last dose interval (days) mean (SD) | 270.6 (101.06) | 223.3 (36.98) | 294.5 (90.88) | |
| Group B (n = 62) | ||||
|
MVC-COV1901
(15 mcg) |
MVC-COV1901
(15 mcg, beta) |
MVC-COV1901
(25 mcg, beta) |
||
| Number of participants, n | 21 | 21 | 20 | - |
| Age | - | |||
| Mean (SD) | 36.8 (9.24) | 38.6 (7.53) | 38.0 (8.98) | 0.8162 a |
| Sex | 0.5530 b | |||
| Male | 8 (38.1%) | 10 (47.6%) | 11 (55.0%) | - |
| Female | 13 (61.9%) | 11 (52.4%) | 9 (45.0%) | - |
| Ethnicity | - | |||
| Asian | 21 (100%) | 21 (100%) | 20 (100%) | - |
| BMI | ||||
| Mean (SD) | 24.44 (3.84) | 24.21 (4.91) | 24.61 (3.97) | 0.8172 a |
| Comorbidities | ||||
| HIV-positive | 0 | 0 | 0 | - |
| HBsAg-positive | 0 | 0 | 0 | - |
| Anti-HCV antibody-positive | 0 | 0 | 0 | - |
| Cardiovascular disease | 0 | 1 (4.8%) | 0 | - |
| Cerebrovascular disease | 1 (4.8%) | 0 | 0 | - |
| Malignancy | 0 | 0 | 1 (5.0%) | - |
| HbA1c higher than the normal range (%) | 2 (9.5%) | 0 | 1 (5.0%) | - |
| 1, 2 dose interval (days) mean (SD) | 38.7 (7.80) | 37.5 (3.04) | 37.6 (2.78) | 0.9774 c |
| 2, 3 dose interval (days) mean (SD) | 111.6 (11.82) | 113.2 (16.44) | 109.2 (9.41) | 0.6995 c |
| Last dose interval (days) mean (SD) | 120.9 (12.20) | 128.0 (28.05) | 123.2 (10.32) | 0.7758 c |
* p-value calculation: a. ANOVA, b. Fisher’s exact test, c. Kruskal–Wallis test.